RxDoctor Payments Data

Dusty Graham

Family · Pinehurst, NCNPI 1083177679

Payments from drug & device makers

$6,381in general payments, 2019–2025

Across 201 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novo Nordisk$826
  • Lilly USA, LLC$473
  • AstraZeneca$375
  • Collegium Pharmaceutical, Inc.$283
  • Scilex Pharmaceuticals Inc.$282
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$6,381100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,381 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,539
Medicare patients
218
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$44,109
EliquisApixaban33$30,085
MounjaroTirzepatide13$13,616
FarxigaDapagliflozin Propanediol11$10,858
JanumetSitagliptin Phos/Metformin Hcl11$8,823
XareltoRivaroxaban11$8,006
Albuterol Sulfate HfaAlbuterol Sulfate66$1,680
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,557
Fluticasone Propionate79$1,471
Gabapentin77$1,243
Rosuvastatin Calcium93$1,152
Omeprazole83$1,072
Diclofenac Sodium17$977
Atorvastatin Calcium92$918
Montelukast Sodium56$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$473$13,61613 claims
AstraZenecaFarxiga$375$10,85811 claims
Almatica Pharma LLCSertraline Hcl$99$20740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →